Search All News
Pathology laboratory screened New York state’s first potential donor—a COVID-19 survivor for antibodies that can be used to treat or vaccine against COVID-19.
Source:CBS New York
Dr. Eldad Hod talks on CBS on harnessing COVID-19 survirors' antibodies to fight the coronavirus disease in others.
NIH is giving out funds to develop seven new testing technologies which could increase testing capacity around the U.S. Daniel Green, MD, was quoted in this article about the RADx program.
They gave scientific presentations covering COVID-19 and non-COVID-19 basic science topics as well as their most current research.
- June 15, 2020
Department of Pathology and Cell Biology thanks CRAC research volunteers and non-CRAC staff for their phenomenal work in building Covid-19 biobank.
Source:Journal of Clinical MicrobiologyJune 11, 2020
Our study provides estimates of the clinical performance of SARS-CoV-2 molecular assays and suggests time frames for appropriate repeat testing ...
Source:Trials JournalJune 10, 2020
The aim of this study is to evaluate the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in hospitalized adults with severe SARS-CoV-2 infection.
- June 2, 2020
We provide an overview of convalescent plasma, including evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials.
Source:Journal of Clinical MicrobiologyMay 14, 2020
Bacteremia is very rare among COVID-19 patients, but blood cultures are overutilized. Consider shortening the incubation period from 5 days to 4 days to free additional capacity.
Source:ScienceDirectMay 14, 2020
Abbott ID Now has limited sensitivity for COVID-19 clinical specimens in transport media with low viral loads, the study shows.
Source:CBS New YorkMay 3, 2020
The elite pilots streaking low over New York and Philadelphia posed a striking thank you to front-line workers like Dr. Sarah Vossoughi, a clinical pathologist at NewYork-Presbyterian/Columbia.
Source:MedPage TodayApril 22, 2020
New York Presbyterian uses two different tests; validation remains a "free-for-all"